Tiehong Yang1, Jian-bing Shen1, Ronghua Yang1, John Redden1, Kimberly Dodge-Kafka1, James Grady1, Kenneth A Jacobson1, Bruce T Liang2. 1. From Pat and Jim Calhoun Cardiology Center, University of Connecticut Medical Center, Farmington, CT (T.Y., J.S., R.Y., J.R., K.D.-K., J.G., B.T.L.); and Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD (K.A.J.). 2. From Pat and Jim Calhoun Cardiology Center, University of Connecticut Medical Center, Farmington, CT (T.Y., J.S., R.Y., J.R., K.D.-K., J.G., B.T.L.); and Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD (K.A.J.). bliang@uchc.edu.
Abstract
BACKGROUND: Heart failure (HF), despite continuing progress, remains a leading cause of mortality and morbidity. P2X4 receptors (P2X4R) have emerged as potentially important molecules in regulating cardiac function and as potential targets for HF therapy. Transgenic P2X4R overexpression can protect against HF, but this does not explain the role of native cardiac P2X4R. Our goal is to define the physiological role of endogenous cardiac myocyte P2X4R under basal conditions and during HF induced by myocardial infarction or pressure overload. METHODS AND RESULTS: Mice established with conditional cardiac-specific P2X4R knockout were subjected to left anterior descending coronary artery ligation-induced postinfarct or transverse aorta constriction-induced pressure overload HF. Knockout cardiac myocytes did not show P2X4R by immunoblotting or by any response to the P2X4R-specific allosteric enhancer ivermectin. Knockout hearts showed normal basal cardiac function but depressed contractile performance in postinfarct and pressure overload models of HF by in vivo echocardiography and ex vivo isolated working heart parameters. P2X4R coimmunoprecipitated and colocalized with nitric oxide synthase 3 (eNOS) in wild-type cardiac myocytes. Mice with cardiac-specific P2X4R overexpression had increased S-nitrosylation, cyclic GMP, NO formation, and were protected from postinfarct and pressure overload HF. Inhibitor of eNOS, L-N(5)-(1-iminoethyl)ornithine hydrochloride, blocked the salutary effect of cardiac P2X4R overexpression in postinfarct and pressure overload HF as did eNOS knockout. CONCLUSIONS: This study establishes a new protective role for endogenous cardiac myocyte P2X4R in HF and is the first to demonstrate a physical interaction between the myocyte receptor and eNOS, a mediator of HF protection.
BACKGROUND:Heart failure (HF), despite continuing progress, remains a leading cause of mortality and morbidity. P2X4 receptors (P2X4R) have emerged as potentially important molecules in regulating cardiac function and as potential targets for HF therapy. TransgenicP2X4R overexpression can protect against HF, but this does not explain the role of native cardiac P2X4R. Our goal is to define the physiological role of endogenous cardiac myocyte P2X4R under basal conditions and during HF induced by myocardial infarction or pressure overload. METHODS AND RESULTS:Mice established with conditional cardiac-specific P2X4R knockout were subjected to left anterior descending coronary artery ligation-induced postinfarct or transverse aorta constriction-induced pressure overload HF. Knockout cardiac myocytes did not show P2X4R by immunoblotting or by any response to the P2X4R-specific allosteric enhancer ivermectin. Knockout hearts showed normal basal cardiac function but depressed contractile performance in postinfarct and pressure overload models of HF by in vivo echocardiography and ex vivo isolated working heart parameters. P2X4R coimmunoprecipitated and colocalized with nitric oxide synthase 3 (eNOS) in wild-type cardiac myocytes. Mice with cardiac-specific P2X4R overexpression had increased S-nitrosylation, cyclic GMP, NO formation, and were protected from postinfarct and pressure overload HF. Inhibitor of eNOS, L-N(5)-(1-iminoethyl)ornithine hydrochloride, blocked the salutary effect of cardiac P2X4R overexpression in postinfarct and pressure overload HF as did eNOS knockout. CONCLUSIONS: This study establishes a new protective role for endogenous cardiac myocyte P2X4R in HF and is the first to demonstrate a physical interaction between the myocyte receptor and eNOS, a mediator of HF protection.
Authors: E C Lee; D Yu; J Martinez de Velasco; L Tessarollo; D A Swing; D L Court; N A Jenkins; N G Copeland Journal: Genomics Date: 2001-04-01 Impact factor: 5.736
Authors: Yi-Heng Li; Anilkumar K Reddy; George E Taffet; Lloyd H Michael; Mark L Entman; Craig J Hartley Journal: Ultrasound Med Biol Date: 2003-09 Impact factor: 2.998
Authors: B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams Journal: Pharmacol Rev Date: 1994-06 Impact factor: 25.468
Authors: Hartmut Ruetten; Stefanie Dimmeler; Doris Gehring; Christian Ihling; Andreas M Zeiher Journal: Cardiovasc Res Date: 2005-02-24 Impact factor: 10.787
Authors: Kazuhisa Kondo; Shashi Bhushan; Adrienne L King; Sumanth D Prabhu; Tariq Hamid; Steven Koenig; Toyoaki Murohara; Benjamin L Predmore; Gabriel Gojon; Gabriel Gojon; Rui Wang; Naveena Karusula; Chad K Nicholson; John W Calvert; David J Lefer Journal: Circulation Date: 2013-02-07 Impact factor: 29.690
Authors: Stefan Janssens; Peter Pokreisz; Luc Schoonjans; Marijke Pellens; Pieter Vermeersch; Marc Tjwa; Peter Jans; Marielle Scherrer-Crosbie; Michael H Picard; Zsolt Szelid; Hilde Gillijns; Frans Van de Werf; Desire Collen; Kenneth D Bloch Journal: Circ Res Date: 2004-03-25 Impact factor: 17.367
Authors: Jian-Bing Shen; Kiran S Toti; Saibal Chakraborty; T Santhosh Kumar; Chunxia Cronin; Bruce T Liang; Kenneth A Jacobson Journal: Purinergic Signal Date: 2020-01-27 Impact factor: 3.765
Authors: Ji Xu; Alexander M Bernstein; Angela Wong; Xiao-Hong Lu; Sheraz Khoja; X William Yang; Daryl L Davies; Paul Micevych; Michael V Sofroniew; Baljit S Khakh Journal: J Neurosci Date: 2016-08-24 Impact factor: 6.167
Authors: Francie Moehring; Ashley M Cowie; Anthony D Menzel; Andy D Weyer; Michael Grzybowski; Thiago Arzua; Aron M Geurts; Oleg Palygin; Cheryl L Stucky Journal: Elife Date: 2018-01-16 Impact factor: 8.140